<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03313505</url>
  </required_header>
  <id_info>
    <org_study_id>16-09</org_study_id>
    <secondary_id>2016-A00901-50</secondary_id>
    <nct_id>NCT03313505</nct_id>
  </id_info>
  <brief_title>PROtein S100B for Mild Trauma of the HEad in Emergency Patients</brief_title>
  <acronym>PROMETHEE</acronym>
  <official_title>PROtein S100B for Mild Trauma of the HEad in Emergency Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Princesse Grace</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Princesse Grace</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brain injury is a frequent purpose for consultation in emergency services. Management of
      brain injury is time and resource consuming, combining clinical monitoring and imaging.

      The stage prior to the management of the victims of brain injury is stratification of the
      severity, potential or proven.

      Severe brain injury requires emergent brain CT-scan, ideally within one hour of the first
      medical contact. Patients requiring this strategy present with focused neurological deficit,
      Glasgow score &lt;15 to 2 hours after the trauma, suspicion of open fracture of the skull or
      dish pan fracture, any signs of fracture of the skull base (hemotympanum, bilateral
      peri-orbital ecchymosis), otorrhea or rhinorrhea of cerebrospinal fluid, more than one
      episode of vomiting in adults, and posttraumatic convulsion. Patients benefiting from
      anticoagulant therapy are included in this category.

      Victims of brain injury that do not fall into this category are considered less critical.

      By definition, mild traumatic brain injury :

        -  a trauma of the cephalic extremity :

        -  whose Glasgow score (30 min after the trauma or during the consultation) is 13-15,

        -  associated with one or more of the following: confusion; disorientation; loss of
           consciousness of 30 min or less; post-traumatic amnesia of less than 24 hours; other
           transient neurological abnormalities (focal signs, epileptic seizures, non-surgical
           intracranial lesion).

      Among these patients, some are considered at risk of developing intracerebral lesions.
      Nevertheless, it should be noted that the prevalence of hemorrhagic complications is
      radically different between patients with a Glasgow score of 13 and those with a score of 15.
      Thus, the recommendations suggest a brain scan without injection of contrast media within 4
      to 8 hours for patients with the following characteristics :

        -  a retrograde amnesia of more than 30 minutes,

        -  a loss of consciousness or amnesia associated with:

             -  either a risk mechanism (pedestrian overturned by a motor vehicle, ejection of a
                vehicle, falling by more than one meter),

             -  or an age&gt; 65 years,

             -  or coagulation disorders, including the use of platelet aggregation therapy.
                Patients who fall outside this definition are considered low risk of complication
                and should not benefit of imaging.

      Data from the scientific literature show that an early brain CT-scan allows identification of
      post-traumatic lesions in this population. Nevertheless, organizational problems, including
      the availability of the imaging, radiation, and disruption of surveillance related to patient
      displacement, are limitations to this strategy. In contrast, the low cost-effectiveness of CT
      scan is often advocated in patients with mild traumatic brain injury. For example, in the
      Octopus study, 52 of 1316 patients who received CT scan after mild head trauma had an
      intracerebral lesion. Among these patients, 39 (3%) had intracerebral lesion related to
      trauma; for 13 (1%) patients, the link with the trauma was uncertain.

      In fact, the search of alternatives for a safer, more conservative, more efficient practice,
      one of the objectives of which is to limit the undue use of cerebral scanning. Thus, many
      teams have been interested in the use of biological variables to guide the decision to use
      imagery.

      Among candidate biomarkers, the S100B protein has been the subject of many evaluations which
      allow it to be used in current practice. Indeed, the increase of the S100B protein carried
      out within 3 hours following a mild head trauma makes it possible to identify the patients at
      risk of intracerebral lesion and to target the indications of imaging.

      The purpose of the registry is to describe the use, interpretation and performance of the
      S100B protein in its use at bedside in emergency medicine.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the number of brain CT-scan saved in patients who have been tested for S100B protein</measure>
    <time_frame>53 weeks</time_frame>
    <description>Percentage (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of supported patients with S100B protein assay or without S100B protein assay</measure>
    <time_frame>53 weeks</time_frame>
    <description>Percentage (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive treatment comparison of the patients included in the centers that carried out an &quot;intensive implementation&quot; of the use of the S100B protein and those included in the centers that provided the S100B protein</measure>
    <time_frame>53 weeks</time_frame>
    <description>Percentage (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification and evaluation of deviations to the algorithm</measure>
    <time_frame>53 weeks</time_frame>
    <description>Percentage (%)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">784</enrollment>
  <condition>Mild Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Patients who had been tested for S100B protein</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients who have benefited from another strategy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S100B protein dosage</intervention_name>
    <description>S100B protein dosage will be carried out, by a blood sample, on the earliest after admission and before 3th hour following brain injury S100B protein dosage will be left to the assessment of the emergency physician in charge of the patient</description>
    <arm_group_label>Patients who had been tested for S100B protein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brain CT scan</intervention_name>
    <description>No injected brain CT-scan, regardless of the time between the brain injury and the arrival in the emergency unit. Realization of CT-scan will be left to the assessment of the emergency physician in charge of the patient</description>
    <arm_group_label>Patients who have benefited from another strategy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients admitted to the emergency unit with mild brain injury and meeting the
        inclusion criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult Patients

          -  Victims of mild head trauma at risk of complication :

             o Adult patients with head trauma with:

          -  retrograde amnesia of more than 30 minutes, or

          -  loss of consciousness or amnesia of the facts associated with:

               -  Either a risky mechanism (pedestrian overturned by a motor vehicle, ejection of a
                  vehicle, drop of more than one meter),

               -  either An age&gt; 65 years,

               -  Either clotting disorders, including platelet aggregation therapy.

               -  either Glasgow Score to 15

          -  Admitted to the emergency department within three hours of the traumatic event.

        Exclusion Criteria:

          -  Refusal to participate at the study

          -  Patients with obstacle to 7 days follow up

          -  Pregnant women

          -  Patients not subject to an health insurance scheme in France or Monaco.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yann-Erick CLAESSENS, PU-PH</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Princesse Grace</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karim TAZAROURTE, PU-PH</last_name>
    <role>Study Director</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yann-Erick CLAESSENS, PU-PH</last_name>
    <phone>+377 97 98 39 69</phone>
    <email>Yann-erick.claessens@chpg.mc</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeannot SCHMIDT, PU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Jeannot SCHMIDT, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Centre Hospitalier Universitaire Henri-Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mehdi KHELLAF, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Mehdi KHELLAF, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Pôle Est</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karim TAZAROURTE, PU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Karim TAZAROURTE, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre MICHELET, PU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Pierre MICHELET, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Metz-Thionville</name>
      <address>
        <city>Metz</city>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas SCHMUTZ, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Thomas SCHMUTZ, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nice, Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Audrey BOURRIER, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Audrey BOURRIER, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nîmes - Hôpital Carémeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Géraud CLARET, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Pierre-Géraud CLARET, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Nord Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick PLAISANCE, PU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Patrick PLAISANCE, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Sud Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre HAUSFATER, PU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Pierre HAUSFATER, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier MIMOZ, PU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Olivier MIMOZ, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas PESCHANSKI, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas PESCHANSKI, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIA Sainte Anne</name>
      <address>
        <city>Toulon</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélien RENARD, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Aurélien RENARD, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Inter-Communal Régional Toulon-La Seyne sur Mer</name>
      <address>
        <city>Toulon</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fanny BARDET, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Fanny BARDET, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie LECOULES, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Nathalie LECOULES, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Princesse Grace</name>
      <address>
        <city>Monaco</city>
        <zip>98000</zip>
        <country>Monaco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yann-Erick CLAESSENS, PU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Yann-Erick CLAESSENS, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Monaco</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>October 13, 2017</last_update_submitted>
  <last_update_submitted_qc>October 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Brain Concussion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protein S</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

